CALY nice revs,maybe some day mms will let it go
Calypte Biomedical Corporation, a public healthcare company dedicated to the
development and commercialization of urine-based diagnostic products and
services, announced that it expects to report that revenues for the year ended
December 31, 2001, more than doubled compared with the same period last year. It
also said operating margins improved sharply in each quarter, culminating in
record quarterly and annual results.
The company said preliminary, unaudited figures indicate that in the fourth
quarter, ended December 31, 2001, it achieved record revenues of approximately
$2,300,000 -- four times higher than the $577,000 realized in the year earlier
quarter. Included in fourth quarter revenues are sales of its HIV-1 viral
lysate, a component used by another manufacturer in its serum-based HIV
diagnostic tests. These sales occur sporadically during the year, and accounted
for approximately 29% of Calypte's revenues for the fourth quarter and 20% for
the full year. Excluding the lysate sales, fourth quarter revenues grew nearly
three fold from a year ago. For the full year ended December 31, 2001, Calypte
expects to report revenues of approximately $6,800,000, a more than 100%
increase over the $3,296,000 recorded for the comparable period in 2000. |
